A carregar...

ACTR-64. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/mTOR INHIBITOR GDC-0084 IN GBM PATIENTS WITH UNMETHYLATED O(6)-METHYLGUANINE-METHYLTRANSFERASE (MGMT) PROMOTER STATUS

BACKGROUND: GDC-0084 is a potent, oral, selective small molecule inhibitor of class I phosphoinositide 3-kinase and mammalian target of rapamycin (PI3K/mTOR). GDC-0084 crosses the blood-brain barrier and achieves a brain / plasma ratio of approximately 1.0. GDC-0084 was given as once daily dosing in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Wen, Patrick, DeGroot, John, Battiste, James, Goldlust, Samuel, Garner, James, Simpson, Jeremy, Kijlstra, Jelle, Olivero, Alan, Cloughesy, Timothy
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847453/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.106
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!